Non-invasive detection of choroidal melanoma via tear-derived protein corona on gold nanoparticles: a machine learning approach
NatureResearch Authors: Hakimeh Rakhshandeh, Ahmad Nasiraei, Hamid Riazi-Esfahani, Babak Masoomian, Fariba Ghassemi, Mojtaba Arjmand, Saeed Heidari Keshel, Fatemeh Atyabi, Rassoul DinarvandAIIM Authors: Megan Ouyang, Josh BronteApproved by President Reda RiffiPublication Date: 9/30/2025Comprehensive Summary
This study investigates a new way to detect choroidal melanoma, the most common type of eye cancer in adults, by analyzing proteins found in tears. Researchers collected samples from healthy adults and patients with melanoma, and exposed isolated proteins to gold nanoparticles, which attract and bind proteins naturally in a "corona" and analyzed with electrospray ionization mass spectrometry (ESI-MS). The resulting spectral data was analyzed with different machine learning models for statistical feature extraction and deep learning image transformations, which showed clear differences between patients and healthy individuals in tear protein profiles, particularly intensity parameters. Through this approach, models like the Random Forest reached about 96% accuracy and deep learning networks like VGG16 were even better at nearly 98%.
Outcomes and Implications
The study's results suggest a promising non-invasive test that could help physicians identify choroidal melanoma earlier than current imaging exams, which often miss the disease in its earliest stages. Earlier detection is crucial because the cancer spreads quickly and carries a poor prognosis once advanced. The tear-based test is painless, quick, and relatively inexpensive, making it practical for routine screening. The combination of tear-based proteomics and AI could overcome limitations of traditional eye exams that often miss crucial early signs. While large groups are necessary to validate this small study, this approach points out a strong potential tool for clinical adoption that could transform how physicians diagnose eye cancers and improve patient outcomes.
Connect medicine with AI innovation.
No spam. Only the latest AI breakthroughs, simplified and relevant to your field.